Cohort profile: The I AM Frontier prospective cohort study in Flanders

Dries Heylen,Charlotte De Clerck,Murih Pusparum,Alejandro Correa Rojo,Rosette Van Den Heuvel,Geert Baggerman,Arnout Standaert,Jan Theunis,Jef Hooyberghs,Gokhan Ertaylan,Nathalie Lambrechts
DOI: https://doi.org/10.1101/2024.05.17.24307470
2024-05-17
Abstract:Purpose: The I AM Frontier cohort was set up to support proof-of-concepts aimed at precision health and more specifically personalized prevention and health promotion. The study was designed to identify patterns, markers and processes, that play a role in the spectrum between health and early onset of disease and may provide actionable information in a clinical setting, taking into account all ethical, legal and logistical aspects. Participants: The first phase of the I AM Frontier study ran for 12 months as a longitudinal small-scale cohort study (n=30) in the Antwerp region of Flanders, Belgium. Participants were employees of the company hosting the study, they did not have a clinical diagnosis and were between 45-60 years old. Findings to date: Even though no severe health problems are recorded at baseline, participants did report several physical complaints. There is a clear difference in longitudinal variation between clinical and research grade omics types, which might affect their respective ability to detect intermediate molecular changes that can be linked to phenotype changes. Future plans: This cohort is being used to further support the design and implementation of a larger population health cohort with selected modalities for investigating feasibility of personalized prevention in real life setting. Future research will build on this longitudinal dataset to derive healthy yearly fluctuations (or normal ranges) at individual level for predicting early on-set deviations Registration: The study was approved by the ethical committee of the Antwerp University Hospital (RegNr:B300201837314).
What problem does this paper attempt to address?